The European Medicines Agency and its London landlord, Canary Wharf Group, will face off in a trial later this week, when the agency attempts to get out of a long lease as Brexit forces it to relocate to Amsterdam.
The trial between the EMA and its landlord is due to begin on 16 January, the High Court of England and Wales has confirmed to Research Fortnight.
The EMA, which must relocate its headquarters to the Dutch capital by March 2019, is locked into a 25-year contract for the first ten floors of a 24-floor, 50,000-square-metre building in London. The lease with Canary Wharf Group runs until 2039 and does not include a tenant break clause, meaning that there is no inbuilt mechanism for the agency to negotiate an early exit.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.